SciBX
Science-Business eXchange

THE DISTILLERY

This week in therapeutics

Indication	Target/marker/ pathway	Summary	Licensing status	Publication and contact information
Infectious disease				
HIV/AIDS	Toll-like receptor 2 (TLR2); TLR3; TLR9	*In vitro* and mouse studies suggest that a combination of TLR2, TLR3 and TLR9 ligands could be an effective vaccine adjuvant. In a murine HIV immunization model, the three TLR ligands together produced better antiviral protection than each ligand alone. *In vitro*, T cells from the triple TLR ligand–treated mice were responsive to lower antigen concentrations than T cells from mice treated with TLR ligand pairs. Next steps include testing the TLR ligand combination in a macaque model of SIV. At least nine companies have TLR agonists in clinical testing for cancer or infectious diseases. ***SciBX* 3(5); doi:10.1038/scibx.2010.156** **Published online Feb. 4, 2010**	Patent cooperation treaty patent application filed; IP available for licensing	Zhu, Q. *et al. J. Clin. Invest.*; published online Jan. 25, 2010; doi:10.1172/JCI39293 **Contact:** Jay A. Berzofsky, National Cancer Institute, Bethesda, Md. e-mail: berzofsk@helix.nih.gov